Cardinal Health shares remain supported by a 'Strong Buy' consensus and a $5 billion buyback expansion, even as the stock navigates recent short-term underperformance relative to the broader healthcare services sector.
Cardinal Health beat profit estimates, raised its buyback authorization, and carries a Strong Buy consensus, supporting a bullish outlook.
McKesson is mentioned as a competitor that has lagged Cardinal Health's YTD and 52-week gains, implying a neutral relative performance.
The SPDR S&P Health Care Services ETF is used as a benchmark, with CAH underperforming it on YTD and three-month bases but outperforming over 52 weeks.
Cardinal Health reported a strong fiscal fourth quarter, with adjusted EPS of $2.91 beating analyst expectations despite a revenue miss. The company is bolstering shareholder returns by increasing its buyback authorization by $5 billion, signaling management's confidence in long-term specialty-led growth.
While Cardinal Health has outperformed the XHS healthcare services ETF over the past 52 weeks, it has lagged behind the index on a year-to-date and three-month basis.